Awareness is a vanity metric.
When major media outlets like CNBC launch "Cures" initiatives, they wrap themselves in the warm glow of human interest stories. They showcase the brave child, the tireless parent, and the photogenic scientist. They treat rare diseases like a PR problem that can be solved with enough prime-time segments.
It is a lie.
Heartstring-tugging narratives do not fund labs. They do not navigate the brutal "Valley of Death" in drug development. In fact, by focusing on the emotional spectacle of rare diseases, we are distracting from the structural rot that makes these conditions "rare" to begin with. We are cheering for the marathon runner while the track is made of quicksand.
The Sentimentality Trap
Mainstream media loves the "one in a million" hook. It suggests that if we just knew these people existed, we would fix the problem. This premise is fundamentally flawed.
The issue isn't that we don't know rare diseases exist. The issue is that the current economic model for drug development is built for blockbusters, not precision. According to the EveryLife Foundation, the total economic burden of rare diseases in the U.S. was nearly $1 trillion in 2019 alone. Yet, we still treat these cases as isolated tragedies rather than a systemic failure of the pharmaceutical market.
When a network pivots to "Rare Disease Stories," they aren't helping. They are participating in Inspiration Porn. They turn patients into mascots for corporate social responsibility. This creates a "charity mindset" that suggests rare disease research should depend on the whims of donors and viewers rather than a fundamental overhaul of how we value human life in the healthcare economy.
The Orphan Drug Act is Being Weaponized
The industry insider secret no one wants to admit? The legislation meant to help rare disease patients—the Orphan Drug Act of 1983—is being exploited by Big Pharma to create protected monopolies.
The Act provides massive tax credits and seven years of market exclusivity. It was a noble idea. Now, it is a loophole. Companies take a drug intended for a broad population, find a "rare" subset or "salami-slice" a common condition into a rare one, and suddenly they have a government-sanctioned monopoly.
I have seen companies spend millions on "awareness" for a rare condition just to justify a $600,000-a-year price tag for a drug that cost them a fraction of that to repurpose. The media covers the "miracle cure" but ignores the predatory pricing model that ensures only those with elite insurance can actually touch it.
Your Data is Being Harvested, Not Used
"Rare disease stories" often end with a call to action: join a registry, share your data, help us find a cure.
Here is the brutal truth: Most patient data is siloed in proprietary databases that don't talk to each other. When you give your data to a media-driven "cure" initiative, you aren't feeding a global brain. You are often feeding a closed-loop system that the media company or its partners own.
True innovation happens through Open Science. It happens when researchers at Harvard can see the raw data from a trial in Tokyo in real-time. But open science doesn't make for good TV. It’s messy, it involves a lot of Excel spreadsheets, and it doesn’t have a protagonist. So, the media gives you the protagonist and skips the science.
The Problem with "National Audiences"
CNBC and its peers brag about bringing these stories to a "national audience."
Why?
The people who can actually fix these problems—molecular biologists, venture capitalists, and FDA regulators—already know the stories. They don't need a 3-minute segment on a morning show. The national audience is there to provide the "eyes" that sell ads to the very pharmaceutical companies that are keeping the prices high.
It’s a circular economy of virtue signaling.
The Logic of the "Long Tail"
We need to stop treating rare diseases as 7,000 distinct, tiny problems. That is the "silo" trap.
Instead, we need to apply the Long Tail theory. In the aggregate, "rare" is common. One in ten Americans has a rare disease. That is 30 million people. If we treated rare diseases as a single, massive market, the investment logic would shift.
But if we do that, we lose the "plucky underdog" narrative. We lose the ability to pick and choose which "rare" person gets to be the face of the week.
The False Promise of Gene Therapy
Every rare disease documentary ends with the promise of gene therapy. "We are on the verge of a cure," the narrator says over footage of a pipette.
Imagine a scenario where we actually have a functional cure for a rare form of blindness. Now, imagine that cure costs $2.1 million per patient. This isn't a thought experiment; it's the reality of drugs like Zolgensma.
The bottleneck isn't the science anymore. It’s the reimbursement architecture. Our insurance systems are designed for monthly premiums and chronic treatments. They are not built for one-time, million-dollar cures.
By focusing on the "miracle" of the cure, media campaigns ignore the "nightmare" of the bill. We are building Ferraris for people who don't have roads. We need to stop talking about the science and start talking about the bank.
The "Expert" Delusion
The "Cures" segments always feature an "expert" from a top-tier hospital. While these doctors are brilliant, they are often part of the problem. They are incentivized by the "publish or perish" culture of academia.
I’ve sat in rooms where researchers refused to share preliminary findings that could save lives because they wanted the "Nature" cover first. The media ignores this ego-driven gatekeeping. They present a unified front of "science" when the reality is a fragmented, competitive, and often petty landscape of institutional ego.
Stop Awareness. Start Infrastructure.
If you actually want to help people with rare diseases, stop watching the stories. Stop sharing the clips.
Start demanding:
- Mandatory Data Interoperability: If a company gets federal funding or Orphan Drug status, their data must be public and machine-readable.
- Value-Based Pricing: We shouldn't pay for "hope." We should pay for outcomes. If the drug doesn't work, the company shouldn't get paid.
- The End of Salami-Slicing: Regulators must stop allowing companies to categorize common ailments as "rare" just to get tax breaks.
The Mic Drop
Awareness is a sedative. It makes you feel like you’ve done something because you clicked "like" on a video of a kid in a wheelchair.
The media companies aren't "curing" anything. They are selling your empathy back to you. They are turning the most desperate people on earth into content to fill the gaps between commercials for the very companies that make the cures unaffordable.
The next time you see a "Rare Disease Story" on a major network, ask yourself: Who is actually profiting from my tears? Because it’s almost never the patient.
Stop looking for the cure on your TV. The cure is in the plumbing of the system, and the plumbing is broken.
Fix the incentives, and the cures will follow. Keep the stories, and you just get more stories.
